Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

CMD 602

Next Previous
Drug Profile

CMD 602

Alternative Names: CMD-602; WT1 TCR T cell therapy - Kuur Therapeutics

Latest Information Update: 23 Feb 2022

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Imperial College of Science, Technology and Medicine; University College London
  • Developer Kuur Therapeutics
  • Class Gene therapies; Immunotherapies; T lymphocyte cell therapies
  • Mechanism of Action Immunologic cytotoxicity; T lymphocyte replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Discontinued Acute myeloid leukaemia; Chronic myeloid leukaemia; Myelodysplastic syndromes

Most Recent Events

  • 23 Feb 2022 Discontinued - Phase-I/II for Acute myeloid leukaemia (Second-line therapy or greater) in Germany, Belgium, United Kingdom (IV)
  • 23 Feb 2022 Discontinued - Phase-I/II for Chronic myeloid leukaemia (Second-line therapy or greater) in United Kingdom (IV)
  • 23 Feb 2022 Discontinued - Phase-I/II for Myelodysplastic syndromes (Second-line therapy or greater) in Germany, Belgium, United Kingdom (IV)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top